Art by Hertz Nazaire

Today, Dec. 8, the Food and Drug Administration approved exa-cel gene therapy for sickle cell disease, making it the first treatment of its kind available to individuals with SCD in the United States. The approval of this potentially curative therapy marks a major advance in the treatment of sickle cell disease; however, there are valid concerns about accessibility and the potential for adverse effects. SCDAA has published a variety of information to help you learn more about this new treatment option.

READ

• SCDAA Statement on Exa-cel Approval
• Exa-cel: What You Need to Know (Warrior FAQ)

WATCH

• FDA Exa-cel Approval: What You Need to Know
• What to Know About Exa-cel with Dr. Lewis Hsu
• What to Know About Exa-cel with Regina Hartfield

Click here to support SCDAA’s mission.